Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabrazyme dosing in pediatric Fabry disease
NCT00701415Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2008
- Primary completion
- Jun 2015
- Modality
- Replacement Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Started Sep 2008; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00701415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701415.